试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-14
Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.
编号:NCT03028909登记状态:入组前撤回企业 / 申办者:MedImmune LLC
药物 / 成分:Oseltamivir、MEDI8852、Placebo
登记的停止原因(原文):Study is withdrawn due to company decision.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-14
Influencing Wound Healing Through the Application of Hyaluronic Acid With Perfluorodecalin and Physalis Angulata Extract After Split Skin Removal From the Thigh - A Study in "Split Wound Design"
编号:NCT03668665登记状态:入组前撤回企业 / 申办者:RWTH Aachen University
药物 / 成分:Ready Medical Post Treatment、Conventionell Treatment
登记的停止原因(原文):no approval by CA
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-13
Study Of The Efficacy And Security Of Ibandronate For Osteoporosis Treatment In A HIV-Infected Patients Cohort
编号:NCT00662077登记状态:入组前撤回企业 / 申办者:Germans Trias i Pujol Hospital
药物 / 成分:Ibandronate、Lifestyle modifications
登记的停止原因(原文):Financial difficulties
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-12
Growth Hormone Use in Adolescents and Adults With Cystic Fibrosis
编号:NCT00287430登记状态:入组前撤回企业 / 申办者:University of Texas Southwestern Medical Center
药物 / 成分:Growth Hormone、Whole body Protein Turnover Study、Dual Energy X-ray Absorptiometry (DEXA)
登记的停止原因(原文):D Hardin not at institution, IRB has no record, no other investigators for study information
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-12
PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
编号:NCT02948101登记状态:入组前撤回企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Anti-CSF1 Monoclonal Antibody PD-0360324、Cyclophosphamide、Laboratory Biomarker Analysis
登记的停止原因(原文):PI's request
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-12
Effect of NMBA on Surgical Conditions in THR
编号:NCT03369782登记状态:入组前撤回企业 / 申办者:Algemeen Ziekenhuis Maria Middelares
药物 / 成分:Rocuronium、Sugammadex、Placebo
登记的停止原因(原文):refocusing of research priorities
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-12
Varenicline for Smoking Cessation in Hospitalized Patients With Psychiatric Disorders
编号:NCT03809897登记状态:入组前撤回企业 / 申办者:Hospital Universitari Vall d'Hebron Research Institute
药物 / 成分:Varenicline、Nicotine patch
登记的停止原因(原文):Budget not sufficient to cover the study scope proposed and recruitment rates expected to be no sufficient.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-11
Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection
编号:NCT03468829登记状态:入组前撤回企业 / 申办者:Ablynx, a Sanofi company
药物 / 成分:ALX-0171 Dose 1、ALX-0171 Dose 2、Placebo
登记的停止原因(原文):ALX-0171 development program was stopped
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-08
Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
编号:NCT02355431登记状态:入组前撤回企业 / 申办者:Incyte Corporation
药物 / 成分:Itacitinib、erlotinib、placebo
登记的停止原因(原文):Study withdrawn before enrolling first patient
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2019-03-08
A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors
编号:NCT02813902登记状态:入组前撤回企业 / 申办者:Massachusetts General Hospital
药物 / 成分:Heliocare with Fernblock PLE technology、Sugar Pill
登记的停止原因(原文):Lack of funding.
查看官方原始记录 ↗